Cardlytics, Inc. (NASDAQ:CDLX) CFO Sells $84,245.20 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 24,778 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $84,245.20. Following the completion of the transaction, the chief financial officer now owns 140,948 shares of the company’s stock, valued at approximately $479,223.20. The trade was a 14.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alexis Desieno also recently made the following trade(s):

• On Friday, January 3rd, Alexis Desieno sold 8,854 shares of Cardlytics stock. The stock was sold at an average price of $3.67, for a total transaction of $32,494.18.

Cardlytics Price Performance

NASDAQ CDLX opened at $2.96 on Friday. Cardlytics, Inc. has a 1-year low of $2.76 and a 1-year high of $20.52. The business’s fifty day moving average price is $3.44 and its 200-day moving average price is $3.72. The stock has a market capitalization of $150.43 million, a price-to-earnings ratio of -0.48 and a beta of 1.54. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.

Hedge Funds Weigh In On Cardlytics

A number of institutional investors have recently bought and sold shares of the stock. Two Sigma Advisers LP raised its holdings in Cardlytics by 44.1% in the 4th quarter. Two Sigma Advisers LP now owns 36,900 shares of the company’s stock worth $137,000 after purchasing an additional 11,300 shares during the period. Two Sigma Investments LP raised its holdings in Cardlytics by 12.5% in the 4th quarter. Two Sigma Investments LP now owns 94,901 shares of the company’s stock worth $352,000 after purchasing an additional 10,508 shares during the period. ProShare Advisors LLC bought a new position in Cardlytics in the 4th quarter worth $43,000. Millennium Management LLC bought a new position in Cardlytics in the 4th quarter worth $535,000. Finally, D. E. Shaw & Co. Inc. raised its holdings in Cardlytics by 97.4% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,131,505 shares of the company’s stock worth $4,198,000 after purchasing an additional 558,235 shares during the period. 68.10% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CDLX shares. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a report on Friday, January 17th. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $6.92.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.